MoCRA registration and listing are not one-time launch tasks. A Korean beauty brand can complete an initial FDA submission and still fall behind when a contract manufacturer changes an address, a formula is revised, a product is discontinued, or a two-year facility renewal arrives without an assigned owner. The challenge in 2026 is therefore less about learning a new acronym and more about operating several compliance clocks at once. This guide separates facility registration renewal, facility-change updates, new product listings, and annual product-listing updates into a practical calendar. It also explains how the Korean manufacturer, U.S. responsible person, importer, and regulatory service provider can divide work without assuming that an FDA registration number means product approval. The article is general information, not legal advice for a specific company.
The Three MoCRA Compliance Clocks
Section 607 of the Federal Food, Drug, and Cosmetic Act, added by the Modernization of Cosmetics Regulation Act of 2022, established cosmetic product facility registration and product listing requirements, subject to specified exemptions. FDA’s final Registration and Listing guidance explains who submits, what information is included, how submissions are made, and when they are due.
The easiest operational model is to separate three clocks:
- Facility clock: registration, changes, and biennial renewal.
- Product clock: listing new marketed products and updating listed information annually.
- Business-change clock: formulas, labels, brand ownership, manufacturing sites, discontinuations, and relisting events that can affect a submission before a routine review date.
A spreadsheet containing one “FDA complete” date is not enough. Each facility and product needs a status, original submission identifier, last accepted date, next review date, change history, and responsible owner.
Registration Is Not Approval
FDA expressly states that cosmetic facility registration and product listing are neither an approval program nor a promotional tool. The agency does not issue certificates for these submissions. A brand should not place “FDA approved,” an FDA logo, or a self-created certificate on a website merely because a facility or product has a submission record.
Registration and listing also do not replace safety substantiation, compliant labeling, adverse-event procedures, good manufacturing practices, or appropriate claim review. They are important data obligations within a broader compliance system.
Facility Registration and Biennial Renewal
Identify the Facility, Not Just the Brand
Facility registration generally concerns establishments that manufacture or process cosmetic products distributed in the United States. Brand owner, responsible person, contract manufacturer, packer, distributor, importer, and warehouse may be separate entities. The actual activities at each site matter, and exemptions require fact-specific review.
Foreign facilities must identify a U.S. agent in the registration. FDA intends to use the FDA Establishment Identifier, or FEI, as the required facility registration number. The agency’s registration and listing portal page directs owners or operators to search for or request an FEI before submitting.
Build the Biennial Renewal Record
Facility registrations must be renewed every two years. A team should not convert that rule into an invented universal anniversary without checking FDA’s current system instructions and the facility’s accepted registration record. In February 2026, FDA announced updated web-portal and informational materials to help cosmetic facilities prepare for biennial renewal.
Create a renewal file at least several months before the applicable cycle. It should verify the facility’s legal name and address, parent company when relevant, U.S. agent, contact details, brand names manufactured or processed at the location, product categories, and FEI. Compare the file with contracts and product listings rather than copying the previous submission unchanged.
Track Facility Changes Within 60 Days
FDA’s registration framework requires updates to facility registration information within 60 days of changes. A corporate name change, address correction, U.S.-agent replacement, or change in submitted information should trigger the regulatory workflow instead of waiting for biennial renewal.
Contract terms should require the facility to notify the brand and responsible person promptly. If information moves through several intermediaries, a 60-day window can disappear before the person who controls the FDA account learns about the change.
Product Listing and Annual Updates
The Responsible Person Owns the Listing Obligation
FDA describes the responsible person as the manufacturer, packer, or distributor whose name appears on the cosmetic label under the applicable law. That party must list each marketed cosmetic product with FDA, including product ingredients, and provide updates annually, unless an exemption applies.
The label identity and listing owner should agree. If a U.S. distributor’s name replaces a Korean brand owner on the label, the parties must determine how that change affects the responsible-person role and existing listings. This decision should be documented before printing new packaging.
Do Not Wait for the Annual Review to List New Products
The statutory framework includes timing for listing a cosmetic product after it is first marketed. Teams should use FDA’s current guidance and submission instructions to establish the specific deadline for each new U.S. launch rather than holding every new SKU until a year-end batch. Add the required regulatory task to the commercialization schedule before the first sale date.
A product master should distinguish a new formula from a shade, size, kit component, gift set, or packaging-only change. FDA permits a single listing submission for multiple cosmetic products with identical formulations or formulations that differ only with respect to colors, fragrances or flavors, or quantity of contents, under the conditions described by the agency. Do not group products solely because the marketing names are similar.
Annual Product-Listing Updates
Annual updating is an opportunity to confirm more than whether the product is still sold. Review the responsible person, facility registration number, product categories, ingredient information, product names, and any information that changed since the prior listing. Use current formula documents and accepted nomenclature rather than an old retailer page.
FDA’s system includes discontinuation and relisting features. A discontinued product should not remain indefinitely in an ambiguous active state simply because it may return someday. Keep the commercial decision, last distribution date, system action, and any later relisting linked in the internal change history.
A Practical 2026 Compliance Calendar
Every Month: Change Monitoring
Hold a short cross-functional review covering facility changes, U.S.-agent changes, new formulas, revised ingredient decks, label ownership, new market dates, discontinued SKUs, and adverse-event contact details. The purpose is not to resubmit everything monthly. It is to identify events that start a regulatory clock.
Maintain a change log with the date discovered, effective date, affected records, owner, required action, target submission date, actual submission date, and FDA acceptance or validation status. A dashboard without source documents is insufficient; link each event to approved formula, label, and facility evidence.
Quarterly: Reconcile Three Master Lists
Compare the commercial SKU list, manufacturing-site list, and FDA submission inventory. Look for products sold but not listed, discontinued products still active, formulas linked to the wrong facility, and registered facilities that no longer manufacture U.S. products. Reconcile direct-to-consumer, retailer-exclusive, marketplace, sample, and professional formats where applicable.
Quarterly review reduces the size of the annual cleanup and reveals ownership gaps. It also helps the importer and retailer receive consistent product identity data.
Before a Biennial Renewal: Run a Dry Review
At least 90 days before the team’s applicable renewal window, confirm account access, FEI, U.S.-agent consent and contact details, legal names, addresses, product categories, and brand relationships. Confirm that the person expected to submit still has authorized access. If using the Electronic Submissions Gateway Next Generation, FDA notes that a new account can take one to three weeks, so account preparation should not be left to the deadline.
Annual Close: Certify Product Data Deliberately
Schedule the annual product-listing review early enough to resolve formula and site discrepancies. Require regulatory, quality, supply chain, and commercial owners to sign off on their fields. Save submission receipts and accepted SPL records in a controlled repository, then assign the next review date.
How Korean and U.S. Partners Should Divide Responsibility
Korean Manufacturer
The manufacturer should control its legal facility identity, FEI-related information, actual manufacturing or processing activities, formula and ingredient records, and timely change notices. It should identify which U.S. brands and products are made at the site and preserve accepted facility-registration records.
U.S. Responsible Person
The responsible person should maintain the product listing, label identity, marketed-product inventory, ingredient and category data, annual updates, discontinuation decisions, and a connection to adverse-event and recall processes. Outsourcing the data entry does not eliminate the need to verify the submission.
Importer, Distributor, and Retailer
These parties should use consistent manufacturer and product data and promptly communicate launch, label, formula, and discontinuation changes. They should not advertise registration as FDA approval. Purchase agreements can define who supplies records, who submits, who reviews, and how quickly changes must be reported.
For J&J TWIN’s Frisco context, the practical opportunity is to create one U.S. launch packet that connects the Korean formula and facility records with the exact English label and commercial SKU. This is a recommended workflow, not a claim about any current client’s compliance status.
Submission Quality-Control Checklist
- Confirm the correct submitting entity and accountable owner.
- Verify legal names, addresses, FEI, and U.S.-agent information.
- Match each marketed product to the correct manufacturing facilities.
- Use the current formula and ingredient nomenclature.
- Choose product categories based on the actual product.
- Document grouped listings and why grouping is permitted.
- Reconcile active, discontinued, and relisted products.
- Save the submitted SPL, receipt, acceptance status, and review evidence.
Cosmetics Direct is FDA’s user-friendly SPL authoring and submission tool. It performs initial validations and submits data for processing. Initial validation is helpful but does not prove that the underlying business facts or regulatory decisions are correct. A technically accepted record can still contain stale or inconsistent source data.
Risks and Limitations
MoCRA contains exemptions for certain small businesses, but those exemptions do not apply to specified product categories, and drug or device status can change the analysis. Company revenue, product type, facility activity, intended use, and corporate relationships require fact-specific review. Voluntary submissions by exempt entities may still require completion of technically mandatory fields in FDA systems.
FDA guidance describes the agency’s current thinking and does not itself create legally enforceable duties unless statutory or regulatory requirements are cited. Portals, implementation guides, validation rules, and agency interpretations can change. This article does not provide a universal deadline for every facility because the applicable record and current FDA instructions must be checked. Obtain qualified regulatory and legal advice for a specific business.
Conclusion & Key Takeaways
A reliable MoCRA calendar separates biennial facility renewal, 60-day facility-change updates, new-product listing events, and annual product-listing updates. It connects those deadlines to formula, label, manufacturing, and commercial records rather than treating FDA submission as an isolated regulatory activity.
Assign one owner for every facility and SKU, review changes monthly, reconcile records quarterly, prepare early for renewal, and preserve accepted submission evidence. For Korean beauty brands building a durable U.S. presence, the goal is not a certificate or marketing badge. It is accurate, current data that supports traceability and responsible market operations.
